This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bollag, R. J. Articles by Isales, C. M. Search for Related Content PubMed PubMed Citation Articles by Bollag, R. J. Articles by Isales, C. M.

Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors¹

Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia (R.J.B., Q.Z., P.P., L.M., L.Z., R.C., H.R., F.Q., K.H.D.), and the Augusta Veterans Administration Medical Center (A.L.M., C.M.I.), Augusta, Georgia 30912

Address all correspondence and requests for reprints to: Carlos M. Isales, M.D., Medical College of Georgia, Institute of Molecular Medicine and Genetics, 1120 15th Street, Augusta, Georgia 30912. E-mail: cisales{at}mail.mcg.edu

Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid peptide synthesized and secreted from endocrine cells in the small intestine. The role of GIP in coupling nutrient intake and insulin secretion, the incretin effect, is well known. We report that GIP receptor messenger RNA and protein are present in normal bone and osteoblast-like cell lines, and that high affinity receptors for GIP can be demonstrated by [¹²⁵I]GIP binding studies. When applied to osteoblast-like cells (SaOS2), GIP stimulated increases in cellular cAMP content and intracellular calcium, with both responses being dose dependent. Moreover, administration of GIP results in elevated expression of collagen type I messenger RNA as well as an increase in alkaline phosphatase activity. Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblast-like cells and that GIP modulates the function of these cells.

This article has been cited by other articles:

				J. Cornish, J. L. Costa, and D. Naot The Bone-Fat Mass Relationship: Laboratory Studies IBMS BoneKEy, September 1, 2009; 6(9): 311 - 322. [Abstract] [Full Text] [PDF]

				W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]

				M. Salehi, B. A. Aulinger, and D. A. D'Alessio Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins Endocr. Rev., May 1, 2008; 29(3): 367 - 379. [Abstract] [Full Text] [PDF]

				C. Yamada, Y. Yamada, K. Tsukiyama, K. Yamada, N. Udagawa, N. Takahashi, K. Tanaka, D. J. Drucker, Y. Seino, and N. Inagaki The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption Endocrinology, February 1, 2008; 149(2): 574 - 579. [Abstract] [Full Text] [PDF]

				Q. Zhong, T. Itokawa, S. Sridhar, K.-H. Ding, D. Xie, B. Kang, W. B. Bollag, R. J. Bollag, M. Hamrick, K. Insogna, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E543 - E548. [Abstract] [Full Text] [PDF]

				Y. Yamada, K. Miyawaki, K. Tsukiyama, N. Harada, C. Yamada, and Y. Seino Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide Diabetes, December 1, 2006; 55(Supplement_2): S86 - S91. [Abstract] [Full Text] [PDF]

				D. B. Henriksen The Gut Feeling of Bone Remodeling IBMS BoneKEy, November 1, 2005; 2(11): 16 - 23. [Full Text] [PDF]

				J. Nyberg, M. F. Anderson, B. Meister, A.-M. Alborn, A.-K. Strom, A. Brederlau, A.-C. Illerskog, O. Nilsson, T. J. Kieffer, M. A. Hietala, et al. Glucose-Dependent Insulinotropic Polypeptide Is Expressed in Adult Hippocampus and Induces Progenitor Cell Proliferation J. Neurosci., February 16, 2005; 25(7): 1816 - 1825. [Abstract] [Full Text] [PDF]

				M. J. Theodorakis, O. Carlson, D. C. Muller, and J. M. Egan Elevated Plasma Glucose-Dependent Insulinotropic Polypeptide Associates With Hyperinsulinemia in Impaired Glucose Tolerance Diabetes Care, July 1, 2004; 27(7): 1692 - 1698. [Abstract] [Full Text] [PDF]

				K.-H. Ding, Q. Zhong, J. Xu, and C. M. Isales Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E773 - E779. [Abstract] [Full Text] [PDF]

				J. A. Clowes, H. C. Allen, D. M. Prentis, R. Eastell, and A. Blumsohn Octreotide Abolishes the Acute Decrease in Bone Turnover in Response to Oral Glucose J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4867 - 4873. [Abstract] [Full Text] [PDF]

				K.-H. Ding, Q. Zhong, and C. M. Isales Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1 Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E390 - E396. [Abstract] [Full Text] [PDF]

				K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]

				J. A. Clowes, R. T. Robinson, S. R. Heller, R. Eastell, and A. Blumsohn Acute Changes of Bone Turnover and PTH Induced by Insulin and Glucose: Euglycemic and Hypoglycemic Hyperinsulinemic Clamp Studies J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3324 - 3329. [Abstract] [Full Text] [PDF]